Media headlines about Anika Therapeutics (NASDAQ:ANIK) have trended positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anika Therapeutics earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.833888832878 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Anika Therapeutics (ANIK) traded down $0.01 during midday trading on Friday, reaching $57.59. 88,487 shares of the company’s stock were exchanged, compared to its average volume of 81,094. The company has a market cap of $844.37, a P/E ratio of 27.17, a P/E/G ratio of 3.49 and a beta of 1.60. Anika Therapeutics has a one year low of $41.64 and a one year high of $69.81.
ANIK has been the topic of several recent analyst reports. First Analysis upgraded shares of Anika Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $45.00 to $68.00 in a research report on Wednesday, January 24th. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 26th. Barrington Research raised their price objective on shares of Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Finally, Sidoti initiated coverage on shares of Anika Therapeutics in a research report on Friday, January 26th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $62.50.
In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of Anika Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.57% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Anika Therapeutics (ANIK) Receives Media Impact Score of 0.26” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/11/anika-therapeutics-anik-receives-media-impact-score-of-0-26.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.